Grifols (GRFS) Revenue Growth (3y) (2013 - 2020)
Grifols (GRFS) Revenue Growth (3y) (2013 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.56% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 7.01% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.37% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 8.00% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 10.45% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.90% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 5.75% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 62.71% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 7.90% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 8.07% |
| Dec 31, 2019 | 25.22% |
| Mar 31, 2019 | 7.52% |
| Dec 31, 2018 | 47.33% |
| Sep 30, 2018 | 7.19% |
| Jun 30, 2018 | 6.09% |
| Mar 31, 2018 | 6.99% |
| Dec 31, 2017 | -3.01% |
| Jun 30, 2017 | -89.63% |
| Mar 31, 2017 | 1.13% |
| Dec 31, 2016 | -92.61% |
| Sep 30, 2016 | 8.16% |
| Jun 30, 2016 | 7.21% |
| Mar 31, 2016 | 5.42% |
| Dec 31, 2015 | -94.64% |
| Sep 30, 2015 | 10.35% |
| Jun 30, 2015 | 9.50% |
| Mar 31, 2015 | 5.49% |
| Dec 31, 2014 | 74.06% |
| Sep 30, 2014 | 10.83% |